2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5839 Circulating tumor cells identify a disseminated genomic high-risk phenotype within ims-IMWG 2025 staging in newly diagnosed multiple myeloma

Yating Li, MD, PhD, Lihui Shi2, Wenqiang Yan3, Lu-Gui Qiu, PhD4, Gang An, MD5
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Background
The 2025 IMS-IMWG consensus genomic staging (CGS) system has improved genomic risk stratification in newly diagnosed multiple myeloma (NDMM), yet does not capture whether high-risk clones have acquired a disseminated phenotype. We investigated whether circulating tumor cells (CTC) could refine CGS and enable longitudinal residual disease monitoring.
Methods
We retrospectively analyzed 631 patients with multiple myeloma from the NICHE cohort (NCT04645199) who underwent peripheral blood CTC assessment across different disease phases. Baseline prognostic analyses were performed in newly diagnosed patients, and longitudinal analyses evaluated the prognostic value of post-treatment CTC detection alone and in combination with bone marrow minimal residual disease (BM-MRD).
Results
Among 410 patients assessed at diagnosis, CTC were detectable in 63.9% and correlated with both bone marrow plasma cell infiltration and the accumulation of high-risk cytogenetic abnormalities. In 359 NDMM patients with adequate follow-up, a cohort-derived CTC threshold of 0.38% independently predicted inferior progression-free survival (PFS) after multivariable adjustment. CTC further refined prognostic stratification specifically within the CGS high-risk subgroup. Patients with CGS high-risk/CTC-high disease had the shortest PFS, defining a disseminated genomic high-risk phenotype that comprised 12.4% (39/314) of evaluable NDMM patients. During follow-up, detectable CTC predicted inferior outcomes in 127 patients assessed during non-progressive disease states, while combined CTC and BM-MRD assessment further stratified outcomes in 120 patients with paired measurements.
Conclusions
Integration of CTC into the IMS-IMWG CGS framework improves identification of patients with disseminated genomic high-risk disease at diagnosis and provides a minimally invasive approach for longitudinal disease monitoring, supporting the clinical utility of CTC assessment throughout the disease course.
Yating Li, MD, PhD: No relevant conflicts of interest to declare.